Pharma giant Bayer China partners with VeChain
|- Renowned pharmaceutical firm Bayer China has collaborated with blockchain firm VeChain.
- The partnership aims to design a blockchain-based platform that increases clinical trial traceability in drugs.
- The platform, CSecure, will be underpinned by blockchain-as-a-service (BaaS)-based tool - ToolChain.
Bayer China, one of the largest pharmaceutical companies in the world, has partnered with blockchain firm VeChain. The partnership aims to design a blockchain-based platform that increases clinical trial traceability in drugs.
The platform, dubbed Csecure, will assign a unique batch number to all the clinical trial drugs entering the blockchain. Through features such as identification codes and time stamps, stakeholders on the blockchain can monitor the drug’s movement along the supply chain in real-time. CSecure will be underpinned by blockchain-as-a-service (BaaS)-based tool - ToolChain. This will allow VeChain to design and build full-fledged distributed ledger technology solutions that meet all clients' requirements.
VeChain CEO and co-founder Sunny Lu said:
We’ve experienced the rigorousness of the medical industry by working with Bayer China. I feel Bayer’s professionalism and superb work ethic towards medicine and healthcare causes as a whole.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.